Tokushima University / Educator and Researcher Directory --- Inoue, Hiroaki

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Natsuki Teruya, Hiroaki Inoue, Rie Horii, Futoshi Akiyama, Takayuki Ueno, Shinji Ohno and Shunji Takahashi : Intratumoral heterogeneity, treatment response, and survival outcome of ER-positive HER2-positive breast cancer, Cancer Medicine, Vol.12, No.9, 10526-10535, 2023. (Summary) ER+HER2+ breast cancer requires most types of systemic therapies perioperatively. However, treatment resistance is often experienced. The current study investigated the predictive and prognostic value of intratumoral heterogeneity and conventional clinicopathological factors in patients with ER+HER2+ breast cancer. This research included two patient cohorts with ER+HER2+ breast cancer. Cohort A included patients who underwent surgery without neoadjuvant chemotherapy (NAC). Cohort B comprised patients who received NAC followed by surgery. Intratumoral heterogeneity was assessed via ER and HER2 double staining, and the number of cells stained with different patterns of ER and HER2 was counted. In total, 11 of 92 tumors in cohort A and four of 45 tumors in cohort B consisted exclusively of double-positive (ER+ and HER2+) cells (homogeneous). The rest had different combinations of cells (heterogeneous). The pathological complete response (pCR) rates differed based on tumoral cell components but not intratumoral heterogeneity. The pCR rate of tumors with ER-HER2+ cells but without HER2- cells was higher than that of others (45.5% vs 4.3%; p = 0.0013). Low ER and PgR Allred scores indicated better pCR rates than high scores (p = 0.0005 and 0.024, respectively). Multivariate analysis showed that the ER Allred score and cell component of ER-HER2+ cells without HER2- cells were independent predictors of pCR (p = 0.0055 and 0.0081, respectively). In cohort B, posttreatment Ki67, but not pCR, was a prognostic factor of DFS and OS (p = 0.028 and 0.017, respectively). The prognostic value of combined posttreatment Ki67 and pCR was superior to that of either alone. Combined pCR and posttreatment Ki67 had an independent prognostic value for DFS and OS (p = 0.0068 and 0.0101, respectively). In ER+HER2+ breast cancer, the presence of ER-HER2+ cells without HER2- cells was independently associated with pCR. Combined posttreatment Ki67 and pCR can be more precise in predicting prognosis than pCR alone. (Keyword) Humans / Female / Breast Neoplasms / Ki-67 Antigen / Prognosis / Neoadjuvant Therapy / Receptor, ErbB-2 / Treatment Outcome / Antineoplastic Combined Chemotherapy Protocols / Receptors, Progesterone (Tokushima University Institutional Repository) ● Metadata: 119227 (Link to Publication Site) ● Publication site (DOI): 10.1002/cam4.5788 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36934442 ● Search Scopus @ Elsevier (PMID): 36934442 ● Search Scopus @ Elsevier (DOI): 10.1002/cam4.5788 (Tokushima University Institutional Repository: 119227, DOI: 10.1002/cam4.5788, PubMed: 36934442)
2.	Naoki Miyamoto, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Kazumasa Okumura, Hiroaki Toba, Naoki Hino, Aya Nishisho, Yukishige Sawaka, Taeko Kawanaka, Hiromitsu Takizawa and Akira Tangoku : Absolute Lymphocyte Count Changes During Neoadjuvant Chemotherapy are Associated With Prognosis of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Patients, Clinical Breast Cancer, Vol.23, No.3, e68-e76, 2023. (Summary) Some reports have shown that absolute lymphocyte count (ALC) is associated with prognosis in breast cancer; however, the impact of ALC changes remains unclear. This study aimed to investigate the relationship between ALC changes during neoadjuvant chemotherapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer patients and disease prognosis. This retrospective cohort study January 2010 to September 2020) included patients diagnosed with HER2-positive breast cancer and treated with trastuzumab-based neoadjuvant chemotherapy. The ALC ratio was defined as the ALC value after administration of the anti-HER2 drug divided by the ALC value before administration. The optimal ALC ratio cut-off value was identified using the receiver operating characteristic curve analysis and Youden's index. The relationship between the ALC ratio and disease-free survival was assessed using the Kaplan-Meier method. Univariate and multivariate analyses were performed using the Cox proportional hazards model. Data from a total of 100 HER2-positive breast cancer patients were analyzed. The cut-off value of the ALC ratio was set as 1.142. The median follow-up period was 52.0 (range: 5.1-123.7) months. The 5-year disease-free survival rates were 88.4% and 60.9% in the high-and low-ALC ratio groups, respectively, and were significantly higher in the high-ALC ratio group (p = .0031). The ALC ratio was an independent prognostic factor in multivariate Cox proportional hazards analysis (p = .0032). HER2-positive breast cancer patients with a higher ALC ratio during trastuzumab-based neoadjuvant chemotherapy may have a better prognosis than their counterparts. (Keyword) Humans / female / Breast Neoplasms / Neoadjuvant Therapy / Retrospective Studies / Receptor, ErbB-2 / Prognosis / Trastuzumab / Disease-Free Survival / Lymphocyte Count / Antineoplastic Combined Chemotherapy Protocols (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clbc.2023.01.005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36682907 ● Summary page in Scopus @ Elsevier: 2-s2.0-85147563272 (DOI: 10.1016/j.clbc.2023.01.005, PubMed: 36682907, Elsevier: Scopus)
3.	Souichiro Sasa, Hiroaki Inoue, INUI Tomohiro, Naoki Miyamoto, Mariko Aoyama, Kazumasa Okumura, Hiroaki Toba, Takahiro Yoshida, Tezuka Miki, Hirose Chieko, Yasuyo Saijo, Hisanori Uehara, Izumori Ayumi, Takahashi Masako, Sasa Mitsunori and Hiromitsu Takizawa : Axillary lymphangioma that developed following COVID-19 vaccination: a case report, Surgical Case Reports, Vol.8, No.1, 131, 2022. (Summary) Extensive vaccination programs are being implemented worldwide for coronavirus disease 2019 (COVID-19). With the spread of vaccination, swelling of the lymph nodes after vaccination is frequently seen. We encountered a patient who developed left axillary lymphadenoma following vaccine administration. The patient was a Japanese woman in her 80 s who had previously undergone surgery for right breast cancer. She received two injections of the Pfizer-BioNTech COVID-19 vaccine in her left arm. Approximately 3 months later, she complained of left axillary swelling, and imaging resulted in a diagnosis of left axillary lymphangioma. In accordance with the patient's wishes, we performed axillary mass resection. The pathological diagnosis was lymphangioma. Our examination findings indicated that congestion of the axillary lymph vessels might have been caused by upper-arm injections of the COVID-19 vaccine. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-022-01488-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35798903 ● Search Scopus @ Elsevier (PMID): 35798903 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-022-01488-5 (DOI: 10.1186/s40792-022-01488-5, PubMed: 35798903)
4.	Youichi Otomi, Saho Irahara, Hiroaki Inoue, Takayoshi Shinya, Hideki Otsuka and Masafumi Harada : Increased ¹⁸F-FDG Uptake in the Axillary Lymph Nodes of Vaccinated Side Associated with COVID-19 Vaccination, Molecular Imaging and Radionuclide Therapy, Vol.31, No.2, 169-171, 2022. (Summary) A 50-year-old female patient underwent (fluorine-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) following modified radical mastectomy for cancer of the left breast. Ten days before the PET/CT, the coronavirus disease-2019 (COVID-19) vaccine was injected intramuscularly into the right deltoid muscle. Increased (F-FDG uptake of maximum standardized uptake value (11.0) was observed in the lymph nodes of the right axilla, which had not been observed in the previous PET/CT. The size of the oval-shaped lymph nodes was up to approximately 11×9 mm; however, it was larger than that observed on the previous PET/CT. We contemplate that the increased (F-FDG uptake was a reactive change in the lymph nodes associated with the COVID-19 vaccine. (Link to Publication Site) ● Publication site (DOI): 10.4274/mirt.galenos.2021.22590 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35771098 ● Search Scopus @ Elsevier (PMID): 35771098 ● Search Scopus @ Elsevier (DOI): 10.4274/mirt.galenos.2021.22590 (DOI: 10.4274/mirt.galenos.2021.22590, PubMed: 35771098)
5.	Ayumi Izumori, Masako Takahashi, Souichiro Sasa, Hiroaki Inoue, Akira Tangoku, Miyuki Kanematsu and 笹三徳 : False-negatives due to poor specimens can be prevented based on the macroscopic findings for breast Vacuum-Assisted Biopsy specimens, The Journal of Medical Investigation : JMI, Vol.69, No.1.2, 51-64, 2022. (Summary) Ultrasound-guided breast tissue biopsy is an essential technique for diagnosing breast disease, but sample errors reduce its accuracy. This study investigated whether the histopathological results can be inferred from the macroscopic findings for Ultrasound-guided breast Vacuum Assisted Biopsy (VAB) specimens. Biopsy specimens from 101 patients who underwent mammary gland VAB were photographed with a smartphone, and the relationships between the macroscopic findings and the pathological results were examined. A significant difference was observed with regard to the presence/absence of turbidity: malignancy was detected in 33/37 (89%) specimens with turbidity and in 2/47 (4%) cases without turbidity (p<0.001). A significant difference was also observed regarding the surface properties:malignancy was detected in 14/70 (19%) smooth specimens and in 24/29 (83%) rough specimens (p<0.001). Also, malignancy was detected in 11/13 (85%) specimens with white spots, and the difference was significant (p<0.001). In addition, the characteristics of intraductal papilloma, fibroadenoma, and mastopathy could be confirmed by macroscopic findings. When needle-biopsy of a lesion that is targeted for resection yields macroscopic findings that match the predicted histopathological findings, it can be thought that the biopsy had been properly performed. This means that false-negatives due to poor specimens can be prevented. J. Med. Invest. 69 : 51-56, February, 2022. (Keyword) VAB / skill of the operator / histopathological findings / accuracy / sample errors (Tokushima University Institutional Repository) ● Metadata: 117012 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.51 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35466146 ● CiNii @ National Institute of Informatics (CRID): 1390010457641004800 ● Summary page in Scopus @ Elsevier: 2-s2.0-85128801196 (Tokushima University Institutional Repository: 117012, DOI: 10.2152/jmi.69.51, PubMed: 35466146, CiNii: 1390010457641004800, Elsevier: Scopus)
6.	Mayumi Ikeuchi, Naoki Hino, Aya Nishisyo, Mariko Aoyama, Miyuki Kanematsu, Hiroaki Inoue, Souichiro Sasa, Tomohiro INUI, Naoki Miyamoto, Kazumasa Okumura and Hiromitsu Takizawa : Drug-induced interstitial pneumonia during perioperative chemotherapy for breast cancer, The Journal of Medical Investigation : JMI, Vol.69, No.1.2, 107-111, 2022. (Summary) Drug-induced interstitial pneumonia (DIP) that occurs during chemotherapy for breast cancer is a rare but a serious adverse event. Treatments of DIP requires interruption of breast cancer treatment, which may affect the patient's prognosis. However, there are few reports which discuss DIP during breast cancer treatments. Purpose of this report is to make clear how DIP occurred and influenced breast cancer treatment in our hospital. A total of 74 patients who started perioperative chemotherapy in Tokushima Municipal Hospital for breast cancer from January 2019 to December 2020 were evaluated for DIP. Patients' and tumors' characteristics, and regimens which caused DIP were investigated. The clinical courses of the DIP patients were also followed up. Twelve of the 74 patients developed DIP. All 12 patients had histories of cyclophosphamide administration;however, the causative drug could not be determined. Ten of the 12 patients were treated with steroids, and all the patients recovered ultimately from the interstitial pneumonia. While chemotherapy was administered in six patients after mild DIP, no relapse of pneumonia was observed. DIP during perioperative chemotherapy for breast cancer was resolved with appropriate treatment. Patients were able to resume breast cancer treatment with minimal interruption. J. Med. Invest. 69 : 107-111, February, 2022. (Keyword) breast cancer / Drug-induced interstitial pneumonia / perioperative chemotherapy (Tokushima University Institutional Repository) ● Metadata: 117020 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.107 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35466130 ● CiNii @ National Institute of Informatics (CRID): 1390854882616723072 ● Search Scopus @ Elsevier (PMID): 35466130 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.107 (Tokushima University Institutional Repository: 117020, DOI: 10.2152/jmi.69.107, PubMed: 35466130, CiNii: 1390854882616723072)
7.	宮本直輝, Hiroaki Inoue, INUI Tomohiro, Soichiroh Sasa, Mariko Aoyama, Hiroaki Toba, Kazumasa Okumura, Takahiro Yoshida, Hiromitsu Takizawa and Akira Tangoku : HER2陽性乳癌患者における術前化学療法開始前の総リンパ球数は予後予測の指標となり得る, Shikoku Acta Medica, Vol.77, No.3,4, 131-136, 2021. (Summary) Purpose : Several studies have shown that peripheral hematologic parameters, such as the absolute lymphocyte count(ALC)and neutrophil to lymphocyte ratio(NLR)can predict the prognosis for malignant tumor. We investigated the relation of these parameter and prognosis before neoadjuvant chemotherapy for human epidermal growth factor receptor-2(HER2)-positive breast cancer patients. Methods : From April 2009 to March 2019, 85 patients diagnosed with HER2‐positive breast cancer and treated with trastuzumab-based neoadjuvant chemotherapy were included in this retrospective cohort study. The optimal cut-off for the NLR and ALC was identified using the receiver operating characteristic(ROC)curve analysis and Youden's index. Results : The median age of patients at the start of treatment was 58．9(range 32‐81)years. The median follow-up time for HER2-positive breast cancer patients was 52．0(range:9．8‐114．3)months. In this period, 11 patients developed recurrence. The low-ALC group showed better disease free survival than the high-ALC group(p=0．0482). There was no significant difference in disease free survival between the low- and high-NLR groups. Conclusion : ALC before neoadjuvant chemotherapy may be a predictor of prolonged disease free survival in HER2‐positive breast cancer patients. (Keyword) HER2陽性乳癌 / 総リンパ球数 / 周術期化学療法 / HER2 breast cancer / neoadjuvant chemotherapy / absolute lymphocyte counts (Tokushima University Institutional Repository) ● Metadata: 116396 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520853835244402176 (Tokushima University Institutional Repository: 116396, CiNii: 1520853835244402176)
8.	Hiroaki Toba, Hiromitsu Takizawa, Mariko Aoyama, Hiroaki Inoue and Akira Tangoku : Comprehensive Interventions for Building a Better Regional Cooperation for Cancer Patients, Journal of Japan Surgical Association, Vol.82, No.7, 1281-1285, 2021. (Summary) <p>Objectives : We introduce our comprehensive interventions for building a better regional cooperation for cancer patients. Methods : We have made a questionnaire survey for community physicians asking whether they can accept cancer patients and what types of medical treatments they can provide. Based on the questionnaire responses, we visualized the information, developed a new critical pathway, and improved the system in a basic hospital. Results : We first organized the information obtained from the questionnaire responses and uploaded the organized information to the basic hospital's homepage for public access. We then developed a new critical pathway for the cooperation among community physicians considering the prophylactic administration of a granulocyte-colony stimulating factor (G-CSF) formulation for treating cancer patients. This treatment was subsequently applied to four patients. Additionally, a community physician was matched with each patient by a medical social worker during the patients' hospitalization. We improved the basic hospital's simple electronic medical record system to reduce the physicians' workloads. As a result, the document creation could be completed within one minute, and so they could relate to approximately 10 times larger number of cases. Conclusions : Satisfactory cancer treatments can be provided for patients by building the better regional cooperative relationships and dividing the roles with community physicians in an earlier time.</p> (Keyword) がん患者の地域連携 / かかりつけ医 / 役割分担 / regional cooperation for cancer patients / community physician / division of roles (Link to Publication Site) ● Publication site (DOI): 10.3919/jjsa.82.1281 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390572404756753792 ● Search Scopus @ Elsevier (DOI): 10.3919/jjsa.82.1281 (DOI: 10.3919/jjsa.82.1281, CiNii: 1390572404756753792)
9.	Akira Tangoku, Hiroaki Toba, Hiroaki Inoue, Soichiroh Sasa, Kazumasa Okumura, Mariko Aoyama, INUI Tomohiro and Hiromitsu Takizawa : [ .N-1 Study]., Japanese Journal of Cancer and Chemotherapy, Vol.47, No.12, 1681-1686, 2020. (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33342983 ● Summary page in Scopus @ Elsevier: 2-s2.0-85098745716 (PubMed: 33342983, Elsevier: Scopus)
10.	Soichiroh Sasa, Hiroaki Inoue, Kazumasa Okumura, Mariko Aoyama, Tomohiro INUI, Hiroaki Toba, Takahiro Yoshida, Yoshimi Bando and Akira Tangoku : A case of juvenile fibroadenoma arising from axillary accessory mammary gland, Shikoku Acta Medica, Vol.76, No.3,4, 185-190, 2020. (Summary) A case is20years old woman. She had previously noticed a mass in the left axilla. The mass grew, so she went to the hospital. Ultrasonography revealed a 71 × 51 mm well-defined tumor in the left axilla. We suspected a benign tumor but could not rule out axillary lymph node metastasis or accessory breast cancer. The findings of fine needle aspiration cytology suggested fibroadenoma or phyllodes tumor. Although we diagnosed fibroadenoma by needle biopsy, a definitive diagnosis was made by tumor resection because it is located in the axilla and large in size, and other diseases such as phyllodes tumors can be distinguished. The histopathological diagnosis of the excised specimen was juvenile fibroadenoma. We report a case of juvenile fibroadenoma arising from the axillary accessory mammary gland. (Keyword) Juvenile fibroadenoma / Axillary accessory mammary gland / Axillary tumor (Tokushima University Institutional Repository) ● Metadata: 115366 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050302315065218304 (Tokushima University Institutional Repository: 115366, CiNii: 1050302315065218304)
11.	Hiroaki Inoue, Akira Hirano, Kaoru Ogura, Mari Kamimura, Akinori Hattori, Hiroko Yukawa, Shiho Sakaguchi, Natsuko Tanaka, Aya Matsuoka, Asaka Kodera and Tadao Shimizu : Breast-conserving surgery without radiation in elderly women with early breast cancer, Surgical Oncology, Vol.31, 22-25, 2019. (Summary) Irradiation after breast-conserving surgery (BCS) decreases the incidence of ipsilateral breast tumor recurrence (IBTR) and breast cancer-related death. However, daily radiation treatments are burdensome to elderly patients, whose risk of IBTR is relatively low. Since 2001, we have offered BCS without radiation to patients meeting our selection criteria. This study assessed the prognosis of the patients who chose this option. Between 2001 and 2014, 203 patients met the selection criteria: aged ≥60 years; pathologically node-negative, hormone-positive breast cancer; a negative surgical margin; and no lymphovascular invasion. Among these patients, 84 and 119 underwent BCS with or without radiation, respectively. IBTR, overall survival (OS), and breast cancer-specific survival (BCSS) were evaluated. The median follow-up duration was 6.2 years. There were no significant differences in tumor size or the number of patients with adjuvant therapy between the groups. The 5-year IBTR rates were 0.9% and 1.6% in the non-irradiated and irradiated groups, respectively (p = 0.308). The 5-year OS rates were 94.1% and 98.7% (p = 0.391). Similarly, the 5-year BCSS rates were 97.2% and 98.7% (p = 0.812). It is suggested that the omission of irradiation could be an option for elderly breast cancer patients who satisfy our criteria. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.suronc.2019.08.008 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31479976 ● Search Scopus @ Elsevier (PMID): 31479976 ● Search Scopus @ Elsevier (DOI): 10.1016/j.suronc.2019.08.008 (DOI: 10.1016/j.suronc.2019.08.008, PubMed: 31479976)

Proceeding of Domestic Conference:

1.	阿部祐也, Souichiro Sasa, Hiroaki Inoue, 行重佐和香, Tomohiro Inui, Mariko Aoyama, Atsushi Morishita, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 乳房石灰化が特異的な経過を示した乳癌術後ホルモン療法中の1症例, 第34回日本乳癌検診学会学術総会, Nov. 2024.
2.	Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, 行重佐和香, Kazumasa Okumura, Masakazu Goto, Yoshimi Bando and Hiromitsu Takizawa : 精査機関である当院におけるPPV3の検討, 第34回日本乳癌検診学会学術総会, Nov. 2024.
3.	Sawaka Yukishige, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Masakazu Goto, Hiroyuki Morino, 吉田友紀子, 宮本容子, Yoshie Imai and Hiromitsu Takizawa : Two cases of surveillance using DWIBS in Li-Fraumeni syndrome, 日本人類遺伝学会第69回大会, Oct. 2024.
4.	阿部祐也, Hiroaki Inoue, Sawaka Yukishige, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : 多職種による介入が効果的であった出血を伴う局所進行乳癌の1例, 第21回日本乳癌学会中国四国地方会, Sep. 2024.
5.	藤稿智宏, Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, Hiroaki Toba, Masakazu Goto, 広瀬敏幸, Hisanori Uehara and Hiromitsu Takizawa : 乳房超音波検査にてhaloを伴い乳癌が疑われたadenosisの1例, 第21回日本乳癌学会中国四国地方会, Sep. 2024.
6.	馬場彩花, Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, Atsushi Morishita, Naoki Miyamoto, 藤本啓介, 竹原恵美, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : 多発肺転移を有するホルモン陽性乳癌に対しエチニルエストラジオールを投与し長期奏功を得た一例, 第21回日本乳癌学会中国四国地方会, Sep. 2024.
7.	Hiroaki Inoue : 乳癌化学療法におけるFNマネージメントとジーラスタ®ボディーポッドの運用, 第21回日本乳癌学会中国四国地方会, Sep. 2024.
8.	Yoshie Imai, Hiroaki Inoue, 宮本容子, 吉田友紀子, Hiroyuki Morino, 湊沙希, Souichiro Sasa, 行重佐和香 and Hiroshi Miyamoto : BRCA2 variant of uncertain significanceと診断された乳癌症例の血縁者に対するサーベイランスの一考, 第31回日本がん予防学会総会, Sep. 2024.
9.	Masakazu Goto, Seiya Inoue, Satoshi Fujiwara, 馬場彩花, 竹原恵美, 行重佐和香, 竹内大平, 藤本啓介, Tomohiro Inui, Hiroyuki Sumitomo, Naoki Miyamoto, Mariko Aoyama, Hiroaki Inoue, Naoya Kawakita and Hiromitsu Takizawa : 当院における食道癌手術の定型化への取り組みと術後短期成績について, 第99回中国四国外科学会総会/第29回中国四国内視鏡外科研究会, Sep. 2024.
10.	阿部祐也, Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : 術前化学療法後に手術を含めた集学的治療を拒否したHER2陽性局所進行乳癌の1例, 第32回日本乳癌学会学術総会, Jul. 2024.
11.	Mariko Aoyama, Hiroaki Inoue, Sawaka Yukishige, Tomohiro Inui, Souichiro Sasa, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 術前診断が困難だった乳腺粘液癌肝転移の1例, 第32回日本乳癌学会学術総会, Jul. 2024.
12.	Tomohiro Inui, Hiroaki Inoue, 細川暉雄, Sawaka Yukishige, Souichiro Sasa, Mariko Aoyama, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 当院におけるトラスツズマブデルクステカン投与例の検討, 第32回日本乳癌学会学術総会, Jul. 2024.
13.	細川暉雄, Hiroaki Inoue, Tomohiro Inui, Sawaka Yukishige, Souichiro Sasa, Mariko Aoyama, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : ペムブロリズマブ投与中に下垂体機能低下を認めたトリプルネガティブ乳癌の1例, 第32回日本乳癌学会学術総会, Jul. 2024.
14.	Souichiro Sasa, Hiroaki Inoue, Sawaka Yukishige, Tomohiro Inui, Mariko Aoyama, 細川暉雄, Atsushi Morishita, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 当院における周術期トリプルネガティブ乳癌に対するペムブロリズマブの使用経験, 第32回日本乳癌学会学術総会, Jul. 2024.
15.	Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, Naoki Miyamoto, Atsushi Morishita, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : CDK4/6阻害剤における有害事象とCARGスコアについての検討, 第32回日本乳癌学会学術総会, Jul. 2024.
16.	Sawaka Yukishige, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : エリブリン投与中の病勢進行形式と末梢血総リンパ球数の関係について, 第32回日本乳癌学会学術総会, Jul. 2024.
17.	Hiroaki Inoue : 《特別企画》20年後に最適な乳がんにおける地域連携，役割分担を明らかにする, 第32回日本乳癌学会学術総会, Jul. 2024.
18.	Hiroaki Inoue, Sawaka Yukishige, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Hiroyuki Morino, 吉田友紀子, 宮本容子, Yoshie Imai, Masakazu Goto and Hiromitsu Takizawa : 当院乳癌患者におけるBRCA遺伝学的検査の現状, 第30回日本遺伝性腫瘍学会学術集会, May 2024.
19.	杉本花奈乃, Hiroaki Inoue, Souichiro Sasa, Tomohiro Inui, 行重佐和香, Mariko Aoyama, Hiroaki Toba, Masakazu Goto, Yoshimi Bando and Hiromitsu Takizawa : 乳頭の硬結で発見された浸潤性小葉癌の1例, 第33回日本乳癌検診学会学術総会, Nov. 2023.
20.	行重佐和香, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Takeshi Oya, Yoshimi Bando, Masakazu Goto and Hiromitsu Takizawa : 乳腺原発神経内分泌腫瘍の1例, 第33回日本乳癌検診学会学術総会, Nov. 2023.
21.	Kansei Komaki, Hisanori Uehara and Hiroaki Inoue : 浸潤癌根治手術後21年目に同側に発症した乳房Paget病, 第20回日本乳癌学会中国四国地方会, Oct. 2023.
22.	阿部祐也, Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, 行重佐和香, Kazumasa Okumura, Naoki Miyamoto, Masakazu Goto, Hiroaki Toba, Takashi Kawanaka and Hiromitsu Takizawa : 顔面のしびれを契機に発見された頭蓋底骨転移に対し放射線治療が有効であった1例, 第20回日本乳癌学会中国四国地方会, Sep. 2023.
23.	細川暉雄, Tomohiro Inui, Sawaka Yukishige, Souichiro Sasa, Mariko Aoyama, Hiroaki Inoue, Hiroaki Toba and Hiromitsu Takizawa : 有害事象マネジメントにより術前ペムブロリズマブ投与を継続しpCRの診断を得たトリプルネガティブ乳癌の1例, 第20回日本乳癌学会中国四国地方会, Sep. 2023.
24.	Sawaka Yukishige, Hiroaki Inoue, Tomohiro Inui, Naoki Miyamoto, Souichiro Sasa, Mariko Aoyama, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 高Ca血症のコントロールに難渋した乳癌多発骨転移の1例, 第98回中国四国外科学会総会/第28回中国四国内視鏡外科研究会, Aug. 2023.
25.	Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, Naoki Miyamoto, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : 高齢乳癌患者におけるCDK4/6阻害剤投与の検討, 第98回中国四国外科学会総会/第28回中国四国内視鏡外科研究会, Aug. 2023.
26.	Tomohiro Inui, Hiroaki Inoue, Souichiro Sasa, Kazumasa Okumura, Mariko Aoyama, Sawaka Yukishige, 井﨑富由実, Naoki Miyamoto, Hiroaki Toba, Yoshimi Bando and Hiromitsu Takizawa : 当院における肉芽腫性乳腺炎治療の検討, 第31回日本乳癌学会学術総会, Jun. 2023.
27.	Sawaka Yukishige, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Hiroaki Inoue, Kazumasa Okumura, Masakazu Goto, Hiroaki Toba, Hiromitsu Takizawa, 甫喜本憲弘 and 頼田顕辞 : 局所皮弁による再建を行った腋窩副乳癌の1例, 第31回日本乳癌学会学術総会, Jun. 2023.
28.	Mariko Aoyama, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Kazumasa Okumura, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : トリプルネガティブ乳癌におけるHER2低発現の有無による臨床病理学的所見と予後の検討, 第31回日本乳癌学会学術総会, Jun. 2023.
29.	Hiroaki Inoue, Souichiro Sasa, Kazumasa Okumura, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, 井﨑富由実, Naoki Miyamoto, Hiroaki Toba and Hiromitsu Takizawa : 高齢乳癌患者におけるCDK4/6阻害剤投与の検討, 第31回日本乳癌学会学術総会, Jun. 2023.
30.	Hiroaki Inoue : 《会長特別企画1》20年後に最適な乳がんにおける地域連携，役割分担を明らかにする, 第31回日本乳癌学会学術総会, Jun. 2023.
31.	Sawaka Yukishige, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Kazumasa Okumura, Hiroyuki Morino, 吉田友紀子, 宮本容子 and Hiromitsu Takizawa : BRCA遺伝学的検査の結果inconclusiveとなった3例, 第29回日本遺伝性腫瘍学会学術集会, Jun. 2023.
32.	Hiroaki Inoue, Souichiro Sasa, Tomohiro Inui, Mariko Aoyama, Kazumasa Okumura, Naoki Miyamoto, Hiroaki Toba, Yoshimi Bando and Hiromitsu Takizawa : 針生検における非浸潤癌周囲のTILsは浸潤癌の存在を予測できるか, 第123回日本外科学会定期学術集会, Apr. 2023.
33.	Hiroyuki Sumitomo, Hiroaki Toba, 井﨑富由実, Taihei Takeuchi, Tomohiro Inui, Shin-ichi Sakamoto, Naoki Miyamoto, Souichiro Sasa, Mariko Aoyama, Hiroaki Inoue, Mika Takashima, Seiya Inoue, Naoya Kawakita, Satoshi Fujiwara, Masakazu Goto, Kazumasa Okumura, Yukikiyo Kawakami and Hiromitsu Takizawa : 大きな縦隔腫瘍に対する気縦隔を用いた縦隔鏡アプローチの有用性, 第123回日本外科学会定期学術集会, Apr. 2023.
34.	Souichiro Sasa, Hiroaki Inoue, INUI Tomohiro, Naoki Miyamoto, Mariko Aoyama, Kazumasa Okumura, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 原因不明の発熱により治療方針決定に難渋した局所進行乳癌の一例, 第32回日本乳癌検診学会学術総会, Nov. 2022.
35.	Hiroaki Inoue, Souichiro Sasa, Tomohiro Inui, Mariko Aoyama, Kazumasa Okumura, Hiroyuki Sumitomo, Naoki Miyamoto, Hiroaki Toba, Yuka Hiroshima and Hiromitsu Takizawa : 当院におけるトモシンセシスガイド下マンモトーム生検の経験, 第32回日本乳癌検診学会学術総会, Nov. 2022.
36.	Souichiro Sasa, Hiroaki Inoue, Tomohiro Inui, Mariko Aoyama, Kazumasa Okumura, 板東真由, Ichiro Hashimoto, Atsuko Yoshida, 山口美代子, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : 多診療科・多職種チーム連携が有用であった妊娠期乳癌の1例, 第10回日本乳房オンコプラスティックサージャリー学会総会, Oct. 2022.
37.	Hiroaki Toba, Hiroaki Inoue, Mika Takashima, Seiya Inoue, Naoya Kawakita, Masakazu Goto and Hiromitsu Takizawa : より良いがんの地域連携体制構築のための包括的な取り組み, 第60回日本癌治療学会学術集会, Oct. 2022.
38.	Hiroaki Inoue, INUI Tomohiro, Souichiro Sasa, Mariko Aoyama, Kazumasa Okumura, Naoki Miyamoto, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 骨髄癌症，硬膜下血腫によりoncological emergencyの状態であったが救命し得た乳癌多発骨転移の1例, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
39.	Mariko Aoyama, Hiroaki Inoue, INUI Tomohiro, Souichiro Sasa, Kazumasa Okumura, Hiroaki Toba, Takahiro Yoshida and Hiromitsu Takizawa : 3次治療でオラパリブが著効したBRCA陽性転移再発乳癌の1例, 第30回日本乳癌学会学術総会(ハイブリッド開催), Jun. 2022.
40.	Kazumasa Okumura, INUI Tomohiro, Souichiro Sasa, Mariko Aoyama, Hiroaki Inoue, Hiroaki Toba, Takahiro Yoshida, Hiromitsu Takizawa and Akira Tangoku : ペムブロリズムマブの免疫関連副作用と考えられた甲状腺中毒，DICを発症しステロイドが著効した1例, 第30回日本乳癌学会学術総会(ハイブリッド開催), Jun. 2022.
41.	INUI Tomohiro, Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Kazumasa Okumura, Naoki Miyamoto, Hiroaki Toba, Hiromitsu Takizawa and Akira Tangoku : 薬剤性肝障害を来したがCDK4/6阻害薬を変更し治療継続し得た2例, 第30回日本乳癌学会学術総会(ハイブリッド開催), Jun. 2022.
42.	Souichiro Sasa, Hiroaki Inoue, INUI Tomohiro, Naoki Miyamoto, Mariko Aoyama, Kazumasa Okumura, Takahiro Yoshida, Hiroaki Toba and Hiromitsu Takizawa : 当院におけるコンパニオン診断目的に行われたBRCA1/2遺伝学的検査の現状とオラパリブの使用経験, 第30回日本乳癌学会学術総会(ハイブリッド開催), Jun. 2022.
43.	Hiroaki Inoue, 山下華乃, Souichiro Sasa, INUI Tomohiro, Mariko Aoyama, Kazumasa Okumura, Naoki Miyamoto, Hiroaki Toba, Takahiro Yoshida, Yoshimi Bando, Hiromitsu Takizawa and Akira Tangoku : 非浸潤癌におけるTILsは浸潤の有無を予測できるか, 第30回日本乳癌学会学術総会(ハイブリッド開催), Jun. 2022.
44.	Hiroaki Inoue, Souichiro Sasa, INUI Tomohiro, Mariko Aoyama, Kazumasa Okumura, Naoki Miyamoto, Hiroaki Toba, Takahiro Yoshida and Hiromitsu Takizawa : エリブリン投与中の末梢血総リンパ球数変化率は進行・再発乳癌の予後予測因子となるか, 第122回日本外科学会定期学術集会(ハイブリッド開催), Apr. 2022.
45.	Soichiroh Sasa, Hiroaki Inoue, Tomohiro INUI, Mariko Aoyama, Kazumasa Okumura, Hiroaki Toba, Takahiro Yoshida, Akira Tangoku, 高橋雅子 and 笹三徳 : 乳腺後隙に発生した急速増大を伴う嚢胞性腫瘤の一切除例, 第31回日本乳癌検診学会学術総会(ハイブリッド開催), Nov. 2021.
46.	Hiroaki Inoue, Soichiroh Sasa, Tomohiro INUI, Mariko Aoyama, Kazumasa Okumura, Hiroaki Toba, Takahiro Yoshida, Hiromitsu Takizawa and Akira Tangoku : 当院におけるAYA世代乳癌患者の発見契機と予後について, 第31回日本乳癌検診学会学術総会(ハイブリッド開催), Nov. 2021.
47.	乾友浩, Hiroaki Inoue, Soichiroh Sasa, Mariko Aoyama, Kazumasa Okumura, 宮本直輝, Hiroaki Toba, Takahiro Yoshida and Hiromitsu Takizawa : アベマシクリブ投与中に重篤な間質性肺炎を来したが救命しえた1例, 第18回日本乳癌学会中国四国地方会(WEB開催), Sep. 2021.
48.	Kazumasa Okumura, INUI Tomohiro, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Hiroaki Toba and Akira Tangoku : 術後補助療法としてのTC療法の治療成績の検討, 第29回日本乳癌学会学術総会(ハイブリッド開催), Jul. 2021.
49.	Soichiroh Sasa, INUI Tomohiro, Mariko Aoyama, Hiroaki Inoue, Kazumasa Okumura, Hiroaki Toba and Akira Tangoku : 乳癌術前化学療法におけるアルブミン懸濁型パクリタキセルの使用経験, 第29回日本乳癌学会学術総会(ハイブリッド開催), Jul. 2021.
50.	Mariko Aoyama, Hiroaki Inoue, INUI Tomohiro, Soichiroh Sasa, Kazumasa Okumura, Hiroaki Toba, Yoshimi Bando and Akira Tangoku : 浸潤性小葉癌の病変の広がり診断についての検討-画像所見と病理学的所見との相関に注目して-, 第29回日本乳癌学会学術総会(ハイブリッド開催), Jul. 2021.
51.	Hiroaki Inoue, Soichiroh Sasa, Mariko Aoyama, Tomohiro Inui, Kazumasa Okumura, Hiroaki Toba, Naoki Miyamoto and Akira Tangoku : 高齢乳癌患者におけるCARGスコアは予後予測因子になるか?, 第29回日本乳癌学会学術総会(ハイブリッド開催), Jul. 2021.
52.	INUI Tomohiro, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Kazumasa Okumura, Hiroaki Toba and Akira Tangoku : 当院における乳癌脳転移症例の検討, 第29回日本乳癌学会学術総会(ハイブリッド開催), Jul. 2021.
53.	山尾雅美, 山口夏美, 松本麻依, 平田有紀奈, 西尾進, Tomohiro Inui, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Kazumasa Okumura, Hiroaki Toba, Takeshi Oya, Yoshimi Bando, Masataka Sata and Akira Tangoku : 硬化性腺症を背景に発生した悪性葉状腫瘍の1例, 第29回日本乳癌学会学術総会(ハイブリッド開催), Jul. 2021.
54.	Hiroaki Toba, INUI Tomohiro, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Kazumasa Okumura and Akira Tangoku : かかりつけ医と役割分担してより良い乳癌診療をするための包括的な取り組み, 第29回日本乳癌学会学術総会(ハイブリッド開催), Jul. 2021.
55.	Soichiroh Sasa, Hiroaki Inoue, Kazumasa Okumura, Mariko Aoyama, INUI Tomohiro, Hiroaki Toba and Akira Tangoku : 当施設におけるステレオガイド下マンモトーム生検の検討, 第30回日本乳癌検診学会学術総会(ハイブリッド形式), Nov. 2020.
56.	INUI Tomohiro, Hiroaki Inoue, Soichiroh Sasa, Mariko Aoyama, Kazumasa Okumura, Hiroaki Toba, Takahiro Yoshida, Yoshimi Bando and Akira Tangoku : 精査機関である当院における針生検の現状, 第30回日本乳癌検診学会学術総会(ハイブリッド形式), Nov. 2020.
57.	庄野隆志, Takeshi Nishino, 南城和正, 山本清成, 牧秀則, INUI Tomohiro, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Seiya Inoue, Masakazu Goto, Kazumasa Okumura, Takahiro Yoshida and Akira Tangoku : 乳癌術後20年目に食道転移をきたした1例, 第82回日本臨床外科学会総会, Oct. 2020.
58.	庄野隆志, Hiroaki Inoue, 山本清成, Tomohiro Inui, Naoki Miyamoto, Soichiroh Sasa, Mariko Aoyama, Kazumasa Okumura, Hiroaki Toba, Takahiro Yoshida and Akira Tangoku : 腹膜播種によるイレウスに対しベバシズマブ+パクリタキセル療法が著効した再発乳癌の1例, 第17回日本乳癌学会中国四国地方会(Web開催), Oct. 2020.
59.	Naoki Miyamoto, Hiroaki Inoue, Soichiroh Sasa, Hiroaki Toba, Masami Morimoto, Hirokazu Takechi, Mariko Aoyama, 竹原恵美, Kai Mizobuchi and Akira Tangoku : HER2陽性乳癌患者における末梢血リンパ球数，好中球リンパ球比についての検討, 第28回日本乳癌学会学術総会(Web開催), Oct. 2020.
60.	Hiroaki Inoue, Soichiroh Sasa, Hiroaki Toba, Masami Morimoto, Hirokazu Takechi, Mariko Aoyama, Naoki Miyamoto, 竹原恵美, Kai Mizobuchi and Akira Tangoku : CARGスコアは高齢者乳癌患者の薬物療法決定に際し有用か?, 第28回日本乳癌学会学術総会(Web開催), Oct. 2020.
61.	Hirokazu Takechi, 松岡由江, 一宮由貴, 三木幸代, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Masami Morimoto, Hiroaki Toba, Takahiro Yoshida and Akira Tangoku : 乳房再建により急速に鬱症状が改善した1例, 第28回日本乳癌学会学術総会(Web開催), Oct. 2020.
62.	Masami Morimoto, 宮本容子, 吉田友紀子, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Hiroaki Toba, Hirokazu Takechi and Akira Tangoku : 臨床遺伝診療部の従事者間で治療方針を決定したBRCAバリアントの1症例, 第28回日本乳癌学会学術総会(Web開催), Oct. 2020.
63.	竹原恵美, Hiroaki Inoue, Soichiroh Sasa, Masami Morimoto, Hirokazu Takechi, Hiroaki Toba, Mariko Aoyama, Naoki Miyamoto, Kai Mizobuchi and Akira Tangoku : 当院における葉状腫瘍の経験とフォローアップの重要性, 第28回日本乳癌学会学術総会(Web開催), Oct. 2020.
64.	山口美代子, 松岡由江, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Masami Morimoto, Hirokazu Takechi and Akira Tangoku : 乳癌患者に対する多職種カンファレンスの充実に向けた取り組み, 第28回日本乳癌学会学術総会(Web開催), Oct. 2020.
65.	Soichiroh Sasa, Hiroaki Inoue, Masami Morimoto, Hirokazu Takechi and Akira Tangoku : 当科で治療を行ったAYA世代乳癌症例の検討, 第28回日本乳癌学会学術総会(Web開催), Oct. 2020.
66.	Hiroaki Inoue, Hiroaki Toba, Soichiroh Sasa, Masami Morimoto, Hirokazu Takechi, Miyuki Kanematsu, 竹原恵美, Kai Mizobuchi and Akira Tangoku : TILsは薬物療法効果予測因子となるか:S-1+低用量ドセタキセルを用いた術前化学療法(N-1 study)における検討, 第120回日本外科学会定期学術集会(Web開催), Aug. 2020.

Et cetera, Workshop:

1.	Hiroaki Inoue : 乳がん腋窩手術の変遷, ピンクリボンとくしま2024, Oct. 2024.
2.	Hiroaki Inoue : アブラキサンの位置付けと当院での使用経験, 乳がんサポーティブケアセミナー2024∼笑顔をめざして∼, Sep. 2024.
3.	Hiroaki Inoue : 乳がん化学療法におけるFNマネジメントについて, がん化学療法セミナー-ジーラスタボディーポッドの果たす役割-, Mar. 2024.
4.	Masakazu Goto, Seiya Inoue, Satoshi Fujiwara, 髙杉遥, 細川暉雄, Sawaka Yukishige, Taihei Takeuchi, Tomohiro Inui, Hiroyuki Sumitomo, Naoki Miyamoto, Shin-ichi Sakamoto, Souichiro Sasa, Atsushi Morishita, Mariko Aoyama, Hiroaki Inoue, Naoya Kawakita, Hiroaki Toba and Hiromitsu Takizawa : 当院における腹臥位胸腔鏡下食道亜全摘術の術後短期成績について, 第36回四国内視鏡外科研究会, Mar. 2024.
5.	Hiroaki Inoue : 個々に応じた乳がん治療, 徳島大学病院フォーラム2024春, Mar. 2024.
6.	Hiroaki Inoue : ``患者力'' ∼正しい情報を得ていますか?∼, ピンクリボンとくしま2023, Oct. 2023.
7.	Hiroaki Inoue : POTENT試験をふまえた乳がん治療, 第二回乳がんサポーティブケアセミナー∼笑顔をめざして∼, Jul. 2023.
8.	住友弘幸, Masakazu Goto, Seiya Inoue, Satoshi Fujiwara, 井﨑富由実, 行重佐和香, 竹内大平, Tomohiro Inui, Shin-ichi Sakamoto, Naoki Miyamoto, Souichiro Sasa, 三崎万理子, Hiroaki Inoue, Mika Takashima, Naoya Kawakita, Kazumasa Okumura, Hiroaki Toba and Hiromitsu Takizawa : 食道癌術後，再建胃管穿孔による右膿胸を生じた1例, 第6回徳島外科医会, Feb. 2023.
9.	Hiroaki Inoue : 乳がんと遺伝子の関係について理解する, 徳島ピンクリボン集会2022, Oct. 2022.
10.	井﨑富由実, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Naoki Miyamoto, Kazumasa Okumura, Hiroaki Toba, Masakazu Goto, 住田智志, Yoshimi Bando and Hiromitsu Takizawa : 巨大石灰化を認めた骨・軟骨化生を伴う乳癌の1例, 第19回日本乳癌学会中国四国地方会, Sep. 2022.
11.	青山理央, Souichiro Sasa, Tomohiro Inui, Mariko Aoyama, Kazumasa Okumura, Hiroaki Inoue, Hiroaki Toba, Masakazu Goto, Takeshi Oya and Hiromitsu Takizawa : 乳腺腺様嚢胞癌の一例, 第19回日本乳癌学会中国四国地方会, Sep. 2022.
12.	Tomohiro Inui, Hiroaki Inoue, Soichiroh Sasa, Mariko Aoyama, Kazumasa Okumura, Naoki Miyamoto, Hiroaki Toba, Takahiro Yoshida and Hiromitsu Takizawa : アベマシクリブ投与中に重篤な間質性肺炎を来したが救命しえた1例, 第5回徳島外科医会, Feb. 2022.
13.	INUI Tomohiro, Hiroaki Inoue, Soichiroh Sasa, Mariko Aoyama, Kazumasa Okumura, Hiroaki Toba, Hiromitsu Takizawa and Akira Tangoku : トラスツズマブ+ペルツズマブ投与にて重度のinfusion reactionを認めたが再投与可能であった1例, 第4回徳島外科医会, Feb. 2021.
14.	Soichiroh Sasa, Hiroaki Inoue, Kazumasa Okumura, Mariko Aoyama, INUI Tomohiro, Hiroaki Toba and Akira Tangoku : 当施設におけるステレオガイド下マンモトーム生検の検討, 第4回徳島外科医会, Feb. 2021.
15.	庄野隆志, Takeshi Nishino, 南城和正, 山本清成, Hidenori Maki, Tomohiro Inui, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Seiya Inoue, Masakazu Goto, Kazumasa Okumura, Takahiro Yoshida and Akira Tangoku : 乳癌術後20年目に食道転移をきたした1例, 第261回徳島医学会学術集会(Web配信), Aug. 2020.
16.	Tomohiro Inui, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Kazumasa Okumura and Akira Tangoku : 乳癌に対するCNB後にNeedle tract seedingを認めた1例, 第261回徳島医学会学術集会(Web配信), Aug. 2020.
17.	Hiroaki Toba, Hiromitsu Takizawa, 庄野隆志, 南城和正, 山本清成, Hidenori Maki, Tomohiro Inui, Shinichi Sakamoto, Naoki Miyamoto, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Mika Takashima, Daisuke Matsumoto, Seiya Inoue, Naoya Kawakita, Masakazu Goto, Takeshi Nishino, Kazumasa Okumura, Takahiro Yoshida, Yukikiyo Kawakami, Mitsuteru Yoshida, Kazuya Kondo and Akira Tangoku : より良いがんの地域連携体制構築のための取り組み, 第261回徳島医学会学術集会(Web配信), Aug. 2020.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

薬剤耐性トリプルネガティブ乳癌に対するmiRNA-433-3p補充療法の可能性 (Project/Area Number: 24K11742 )
iPS細胞から誘導した気管支肺胞幹細胞を用いたがん幹細胞研究 (Project/Area Number: 23K08319 )
センチネルリンパ節の腫瘍免疫応答に着目した乳癌の新規免疫療法確立のための探索研究 (Project/Area Number: 20K17584 )
Search by Researcher Number (20792378)

Associate Professor : Inoue, Hiroaki

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Proceeding of Domestic Conference:

Et cetera, Workshop:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)